RNASET2

Across TCGA pan-cancer cohorts, RNASET2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RNASET2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RNASET2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RNASET2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where RNASET2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.942	0.991	.026	12	view →
CCRCC	DFS	Median	All	0.709	1.000	.010	12	view →
PDAC	DFS	Quartile	II,III,IV	0.310	0.514	.041	4	view →
LUAD	OS	Tertile	II,III,IV	0.869	0.323	.033	4	view →
LSCC	OS	Quartile	All	0.999	0.837	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RNASET2–HNSC (OS)

Open the HNSC breakdown →